Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA (NYSE: NYXH) is a pioneering health technology company focused on innovative treatments for sleep disordered breathing, particularly Obstructive Sleep Apnea (OSA). This page serves as the definitive source for official updates about their FDA-cleared Genio neurostimulation system, financial developments, and clinical research progress.
Investors and medical professionals will find curated press releases covering regulatory milestones, partnership announcements, and quarterly earnings reports. All content is sourced directly from company filings and verified channels to ensure accuracy.
Key focus areas include updates about international market expansions, clinical trial outcomes for OSA therapies, and technological enhancements to the Genio platform. Bookmark this page to stay informed about Nyxoah's progress in developing patient-centric solutions for chronic sleep conditions.
Nyxoah SA announced significant shareholding updates on April 20, 2023. The company received two transparency notifications regarding large shareholdings. Together Partnership has surpassed the 10% threshold, holding 2,948,285 shares or 10.42% of voting rights as of March 30, 2023. Simultaneously, ResMed Inc. crossed the 5% threshold, holding 1,499,756 shares or 5.30% of voting rights on the same date. The total number of voting rights on that date was 28,286,985. These notifications comply with the regulations set forth in the Act of May 2, 2007.
FAQ
What is the current stock price of NYXOAH S A (NYXH)?
What is the market cap of NYXOAH S A (NYXH)?
